Results 131 to 140 of about 2,360,806 (280)

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini   +11 more
wiley   +1 more source

Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1029-1053, April 2025.
Advanced tumors and ineffective cancer treatments can lead to metastases in distant organs. The sole expression of microRNA 200c (miR‐200c) in breast cancer cells is shown to significantly reduce metastasis formation in xenograft mouse models. Various in vitro analyses revealed impeded migratory behavior, upon miR‐200c expression, as one prerequisite ...
Bianca Köhler   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy